查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球临床诊断市场 - 2023-2030 年
市场调查报告书
商品编码
1316234

全球临床诊断市场 - 2023-2030 年

Global Clinical Diagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球临床诊断市场规模达到 732 亿美元，预计到 2030 年将达到 1,100 亿美元，实现利润丰厚的增长。在预测期内（2023-2030 年），全球临床诊断市场预计将呈现 5.3% 的复合年增长率。

在分子诊断方法中，对遗传物质（DNA 或 RNA）进行分析，以发现与疾病相关的遗传变异、突变或特定生物标志物。被称为聚合酶链反应（PCR）的常用分子技术可扩增和检测特定的 DNA 序列。基因检测、传染病检测、癌症分析和遗传病检测都使用分子诊断技术。

市场动态

活跃的主要参与者推动了预测期内全球临床诊断市场的增长

2023 年 2 月，罗氏公司表示，为了进一步推动其研究和创新工作，该公司加强了与杨森生物技术公司的合作，共同开发用于靶向治疗的辅助诊断产品。

随着新合作关系的扩大，罗氏和杨森将有更多的选择，共同开展精准医疗领域的辅助诊断项目，包括免疫组化（IHC）、数字病理学、新一代测序、聚合酶链反应和免疫测定。

技术进步为全球临床诊断市场带来增长机会

2023 年 3 月，塔塔家族新成立的医疗保健公司塔塔医疗与诊断公司（Tata MD）与总部位于钦奈的安德森诊断与实验室公司（Anderson Diagnostics & Labs，ADL）合作，努力实现本地开发的 Tata MD CHECK 的标准化并降低新感染率。

通过与 ADL 临床专家的合作，"印度制造 "的 Tata MD CHECK 诊断试剂盒现在可以迅速推广。ADL已经成功完成了超过10,000次COVID测试，使用的是基于Feluda CRISPR平台、经DGCA批准的新型诊断解决方案。"在对 10,000 多份样本进行测试和验证后，我们相信这项技术既是最前沿的，也是世界上最好的。

COVID-19 影响分析

COVID-19 大流行对临床诊断市场产生了重大影响。COVID-19 大流行引发了临床诊断研究与开发。专为检测 COVID-19 而开发的新诊断方法、技术和平台迅速发展起来。这些发展有助于抗击大流行病，并产生了有助于整个临床诊断行业的新想法和新信息。

俄乌冲突分析

俄乌战争对临床诊断市场的影响是复杂和多方面的。由于缺乏基础设施、资源和知识，在受冲突影响的地区可能很难获得新的诊断技术。尖端诊断技术（包括分子诊断或成像技术）的使用和获取可能会受到限制，这可能会影响诊断服务的准确性和彻底性。

目 录

第 1 章：研究方法与范围

  • 研究方法
  • 报告的研究目标和范围

第2章：定义和概述

第 3 章：执行摘要

  • 按测试摘录
  • 按产品划分
  • 按最终用户划分
  • 按地区划分

第四章：动态

  • 影响因素
    • 驱动因素
      • 疾病负担加重
    • 制约因素
      • 严格的监管要求
    • 机会
      • 技术进步
    • 影响分析

第 5 章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章：COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • COVID-19 期间的情景
    • COVID-19 后的情况
  • COVID-19 期间的定价动态
  • 供求关系
  • 大流行期间与市场相关的政府倡议
  • 制造商的战略倡议
  • 结论

第 7 章 ：俄乌战争分析

第8章： 人工智能分析

第9章：按检测项目划分

  • 血脂分析
  • 肝功能
  • 肾功能检查
  • 全血细胞计数
  • 电解质检测
  • 传染病检验
  • 其他检验

第 10 章：按产品分类

  • 仪器
  • 试剂
  • 其他

第 11 章：按最终用户分类

  • 医院实验室
  • 诊断实验室
  • 床旁检测
  • 其他

第 12 章：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第 13 章 ：竞争格局

  • 竞争格局
  • 产品基准
  • 公司份额分析
  • 主要发展和战略

第 14 章：公司简介

  • Abbott Laboratories
    • 公司概况
    • 产品组合和说明
    • 财务概况
    • 主要发展
  • Becton, Dickinson and Company
  • BioMerieux
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Siemens AG
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific

第 15 章 ：附录

简介目录
Product Code: CD6523

Market Overview

The global clinical diagnostics market reached US$ 73.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 110.0 billion by 2030. The global clinical diagnostics market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

In molecular diagnostic methods, genetic material (DNA or RNA) is analyzed to find genetic variants, mutations, or particular biomarkers linked to diseases. The commonly used molecular technique known as polymerase chain reaction (PCR) amplifies and detects particular DNA sequences. Genetic testing, infectious disease testing, cancer profiling, and the detection of genetic diseases all use molecular diagnostics.

Market Dynamics

Active Major Players are Boosting the Global Clinical Diagnostics Market Growth During the Forecast Period

In February 2023, In order to further boost its research and innovation efforts, Roche stated that it had increased its partnership with Janssen Biotech Inc. to develop companion diagnostics for targeted treatments.

With the new, enlarged partnership, Roche and Janssen will have more options to work together on companion diagnostics projects in the area of precision medicine, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

Technological Advancements Provide Global Clinical Diagnostics Market Growth Opportunities

In March 2023, In an effort to standardize the locally developed Tata MD CHECK and reduce the rate of new infections, Tata Medical and Diagnostics (Tata MD), a new healthcare company from the Tata family, has partnered with Chennai-based Anderson Diagnostics & Labs (ADL).

The "Made-in-India" Tata MD CHECK diagnostic kit can now be scaled up quickly due to the collaboration with ADL's clinical experts. ADL has already successfully completed over 10,000 COVID tests using this new, DGCA-approved, novel diagnostic solution based on the Feluda CRISPR Platform. "After testing and validating more than 10,000 samples, we believe this technology to be both cutting edge and on par with the best in the world.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical diagnostics market. Clinical diagnostics research and development have been sparked by the COVID-19 pandemic. New diagnostic assays, technologies, and platforms made specifically for the detection of COVID-19 have developed quickly. These developments have aided in the fight against the pandemic and have generated new ideas and information that will help the clinical diagnostics industry as a whole.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the clinical diagnostics market is complex and multifaceted. Due to a lack of infrastructure, resources, and knowledge, access to new diagnostic technology may be difficult in conflict-affected areas. The use and accessibility of cutting-edge diagnostic techniques, including molecular diagnostics or imaging technology, may be constrained, which could have an impact on the accuracy and thoroughness of diagnostic services.

Segment Analysis

The global clinical diagnostics market is segmented based on test, product, end-user, and region.

The Lipid Panel Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The lipid panel segment accounted for the highest market stake accounting for approximately 32.3% of the clinical diagnostics market in 2022. The lipid panel measures different lipids (fats) and the characteristics that go along with them in the bloodstream. It offers significant details on a person's lipid profile and cholesterol levels, which are essential markers of cardiovascular health.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol are both measured as well as the overall amount of cholesterol in the blood. Healthcare providers can determine a patient's risk for cardiovascular disease based on the findings of a lipid panel test and offer medication, lifestyle changes, or other therapies as necessary.

Geographical Analysis

Asia Pacific is Expected to hold Around 25.7% Share of this Market due to Increasing Collaborations and Partnerships Among the Key Players, and Advancement in Clinical Diagnostics

Asia Pacific is expected to hold around 25.7% share of this market. For instance, in May 2023, a high-end diagnostic solutions provider called Core Diagnostics, with its headquarters in Gurugram, announced the opening of a new satellite facility in East Delhi's Hargobind Enclave. With this strategic growth, the company hopes to increase its testing capabilities and give patients and healthcare professionals better access to high-quality diagnostic services.

The satellite lab is a crucial component of Core Diagnostics' strategic expansion plan, which aims to increase the company's testing capacity and satisfy the increasing demand for quality and timely diagnostic services. By bringing superior diagnostic options closer to healthcare professionals and patients, they are able to give them the precise information they need to make prompt medical decisions.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, Thermo Fisher Scientific among others.

Why Purchase the Report?

  • To visualize the global clinical diagnostics market segmentation based on the test, product, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of clinical diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global clinical diagnostics market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test
  • 3.2. Snippet by Product
  • 3.3. Snippet by End-user
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising burden of disease
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent regulatory requirements
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 9.1.2. Market Attractiveness Index, By Test
  • 9.2. Lipid Panel*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Liver Panel
  • 9.4. Renal Panel
  • 9.5. Complete Blood Count
  • 9.6. Electrolyte Testing
  • 9.7. Infectious Disease Testing
  • 9.8. Other Tests

10. By Product

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.1.2. Market Attractiveness Index, By Product
  • 10.2. Instruments*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Reagents
  • 10.4. Others

11. By End-user

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 11.1.2. Market Attractiveness Index, By End-user
  • 11.2. Hospital Laboratory*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Diagnostic Laboratory
  • 11.4. Point-of-care Testing
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Abbott Laboratories*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Becton, Dickinson and Company
  • 14.3. BioMerieux
  • 14.4. Bio-Rad Laboratories Inc.
  • 14.5. Danaher Corporation
  • 14.6. Siemens AG
  • 14.7. Hologic Inc.
  • 14.8. Qiagen NV
  • 14.9. F. Hoffmann-La Roche AG
  • 14.10. Thermo Fisher Scientific

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us